UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

 

(Amendment No. 5)

 

 

ONCOCYTE CORPORATION

(Name of Issuer)

 

Common Stock, no par value		68235C107
(Title of class of securities)		(CUSIP number)

 

Russell Skibsted

Chief Financial Officer

BioTime, Inc.

1010 Atlantic Avenue

Suite 102

Alameda, California 94501

(510) 521-3390

(Name, address and telephone number of person authorized to receive notices and communications)

 

August 14, 2018

(Date of event which requires filing of this statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box ☐.

 

Note: When filing this statement in paper format, six copies of this statement, including exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

 

(Continued on following page(s))

 

 

 

CUSIP No. 04624N 10 7

13D

 

		NAME OF REPORTING PERSON:
		BioTime, Inc.
	1	S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON:
		94-3127919
		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:	(a)	☐
	2		(b)	☐
		SEC USE ONLY
	3
		SOURCE OF FUNDS:
	4
		PF; OO
		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E):		☐
	5
		CITIZENSHIP OR PLACE OF ORGANIZATION:
	6
		California

		SOLE VOTING POWER:
	7
		14,674,244
NUMBER OF		SHARED VOTING POWER:
SHARES	8
BENEFICIALLY		0
OWNED BY
EACH		SOLE DISPOSITIVE POWER:
REPORTING	9
PERSON WITH		14,674,244
		SHARED DISPOSITIVE POWER:
	10
		0

		AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON:
	11
		14,674,244
		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:		☐
	12
		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):
	13
		36.1%(1)
		TYPE OF REPORTING PERSON:
	14
		CO; PH

 

(1)	Based on 40,664,496 shares of common stock outstanding as of August 8, 2018 reported by the Company in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2018.

 

 

This Amendment No 5 (“Amendment No. 5”) amends and supplements the Statement on Schedule 13D dated December 30, 2015, as amended by Amendment No.1 dated August 29, 2016, by Amendment No. 2 dated November 15, 2017, by Amendment No. 3 dated April 3, 2018, and by Amendment No. 4 dated May 17, 2018 (the “Schedule 13D”) relating to the common stock, no par value (“common stock’), of OncoCyte Corporation, a California corporation (the “Company”), and is being filed and is filed by and on behalf of BioTime, Inc. (the “BioTime” or the “Reporting Person”). Unless otherwise defined herein, all capitalized terms used herein shall have the meanings previously ascribed to them in the previous filing of the Schedule 13D.

 

ITEM 1.

SECURITY AND ISSUER

 

This Amendment No. 5 relates to the common stock of the Company and is being filed pursuant to Rule 13d-1 under the Exchange Act. The address of the principal executive offices of the Company is 1010 Atlantic Avenue, Suite 102, Alameda, California 94501.

 

ITEM 2.

IDENTITY AND BACKGROUND

 

(a) This Schedule 13D is being filed on behalf of BioTime, Inc., a California corporation as BioTime.

 

(b) The address of the principal office of BioTime is BioTime, Inc., 1010 Atlantic Avenue, Suite 102, Alameda, California 94501.

 

(c) BioTime is a biotechnology company focused on the emerging field of regenerative medicine.

 

(d) BioTime has not during the last five years been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

 

(e) BioTime has not during the last five years been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

(f) BioTime is organized under the laws of the state of California.

 

 

ITEM 3.

SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

 

The information on BioTime’s cover sheet to this Amendment No. 5 is incorporated by reference herein. There has been no material change from the information last reported in Item 3 of the Schedule 13D.

 

ITEM 4.

PURPOSE OF TRANSACTION

 

BioTime is filing this Amendment No. 5 to report the reduction in its percentage ownership of the outstanding common stock of the Company resulting from the issuance of additional shares of common stock by the Company. BioTime’s percentage ownership of the outstanding common stock is based on the number of outstanding shares of common stock as of August 8, 2018 reported by the Company in its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2018, filed with the Securities and Exchange Commission on August 14, 2018.

 

Except as described above in this Item 4, the Board of Directors of BioTime has not approved any plans or proposals that relate to or would result in: (a) the acquisition by any person of additional securities of the Company, or the disposition of securities of the Company; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Company or any of its subsidiaries; (d) any change in the present Board of Directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the Board; (e) any material change in the present capitalization or dividend policy of the Company; (f) any other material change in the Company’s business or corporate structure; (g) changes in the Company’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Company by any person; (h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act; or (j) any action similar to any of those enumerated above.

 

Although BioTime owns less than a majority of the issued and outstanding shares of common stock of the Company, three of the seven members of the Company Board are members of BioTime’s Board of Directors, and another director of the Company who is not a director or officer of BioTime is the Chief Executive Officer of the Company. BioTime may, through the action of persons who serve on the Company Board acting in conjunction with directors of the Company who are not affiliated with BioTime, from time to time cause the Company to engage in any or all of the kinds of transactions described in the immediately preceding paragraph. BioTime acting alone (if BioTime holds a majority of the shares represented and voting at a meeting where a quorum is present), or BioTime acting in conjunction with other shareholders of the Company (if the vote of a majority of the outstanding shares of Company common stock or a majority of the shares of common stock eligible to vote is required for the applicable action), may, directly or through the action of the Company Board, (1) cause the Company to expand the size of the Company Board and to elect additional directors, (2) cause the Company to reduce the size of the Company Board, (3) nominate persons to stand for election as directors at any annual or special meeting of shareholders of the Company at which directors are to be elected, (4) cause any incumbent director not to be nominated to stand for election as a director at any annual or special meeting of shareholders of the Company at which directors are to be elected, (5) remove any director with or without cause by a vote at any annual or special meeting of shareholders of the Company at which directors are to be elected, or by written consent without a vote, (6) in the event of the death or resignation or removal of a director of the Company, elect a replacement director, and (7) amend the Bylaws or the Articles of Incorporation of the Company. Any such newly elected directors may be officers, directors, or affiliates of BioTime or may be “independent” directors (under Section 8.03(A) of the NYSE American Company Guide or the rules of any other national securities exchange).

 

 

BioTime may also, from time to time, through the action of officers or directors of BioTime who serve on the Company Board acting with other Company directors who are not affiliated with BioTime, cause the Company to (i) offer and sell additional securities, including to BioTime, in order to raise capital for the Company’s operations or to acquire one or more businesses or assets for use in the Company’s business, or for other purposes, (ii) acquire from the Company common shares of BioTime presently owned by the Company, and (iii) if and when opportunities present themselves, cause the Company to enter into one or more merger agreements or other agreements to acquire other business or assets, or merger or consolidation agreements in which the Company is not the surviving corporation.

 

ITEM 5.

INTEREST IN SECURITIES OF THE ISSUER

 

(a) As of the date of this Amendment No. 5, BioTime beneficially owns 14,674,244 shares of Company common stock representing approximately 36.1% of the outstanding common stock of the Company based on the number of outstanding share determined as provided in Item 4.

 

(b) As of the date of this Amendment No. 5, BioTime has sole power to vote or to direct the vote, and sole power to dispose or direct the disposition of, 14,674,244 of the shares of Company common stock it beneficially owns. BioTime disclaims beneficial ownership of 73,176 of the shares of Company common stock held by Asterias Biotherapeutics, Inc. (“Asterias”) as of June 30, 2018. BioTime owns approximately 39.2% of the common stock of Asterias and four Related Directors serve on the Board of Directors of Asterias.

 

(c) During the past sixty days, BioTime has not engaged any transactions in Company common stock.

 

(d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Company common stock beneficially owned by BioTime.

 

(e) Not applicable.

 

 

ITEM 6.

CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

 

There has been no material change from the information last reported in the Schedule 13D.

 

ITEM 7.

MATERIAL TO BE FILED AS EXHIBITS.

 

None

 

 

SIGNATURES

 

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information contained in this statement is true, complete and correct.

 

Dated: August 22, 2018	BIOTIME, INC.
	a California corporation
	By:	/s/ Russell Skibsted
		Russell Skibsted,
		Chief Financial Officer